3 days popular7 days popular1 month popular3 months popular

Colon Cancer Patients Who Consume Too Much Starchy, High Carbohydrate Food At Greater Risk For Cancer Recurrence

Colon survivors whose diet is heavy in complex sugars and carbohydrate-rich foods are far more likely to have a recurrence of the disease than are patients who eat a better balance of foods, a new study by Dana-Farber Institute researchers indicates.

The connection is especially strong in patients who are overweight or obese, the authors write. More than 1,000 patients with advanced (stage III) colon cancer participated in the study, one of the first to examine how diet can affect the chances that the disease will recur. The findings are published online by the Journal of the and will appear later in the journal’s print edition.

Although the results point to a potential hazard, for colon cancer patients, of a high-carbohydrate diet, the take-home message is not a conclusive “Eat less sugar,” said lead author Jeffrey Meyerhardt, MD, MPH. “Our study certainly supports the idea that diet can impact the progression of colon cancer, and that patients and their doctors should consider this when making post-treatment plans. But further research is needed to confirm our findings.”

Recent studies have shown that survivors whose diet and activity patterns lead to excess amounts of insulin in the blood have a higher risk of and death from the disease. High insulin levels can be produced by eating too many starchy and sugar-laden foods. In a previous study of advanced-stage colon cancer patients, Meyerhardt and his colleagues found that those with a typical “Western” diet — marked by high intakes of meat, fat, refined grains, and sugar desserts — were three times more likely to have a than those whose diets were least Western. The new study was conducted to explore which component of the Western diet is most responsible for the increased risk of recurrence.

The study involved 1,011 who had undergone surgery and participated in a National Cancer Institute-sponsored Cancer and Leukemia Group B clinical trial of follow-up chemotherapy for their disease. Participants reported their dietary intake during and six months after the trial.

Researchers tracked the patients’ total carbohydrates, as well as their glycemic index (a measure of how quickly blood sugar levels rise after eating a particular food), and glycemic load (which takes into account the amount of a carbohydrate actually consumed), and looked for a statistical connection between these measures and the recurrence of colon cancer.

They found that participants with the highest dietary levels of glycemic load and had an 80 percent increased risk of colon cancer recurrence or death compared with those who had the lowest levels. Among patients who were overweight or obese (had a body mass index above 25 kg/m2), the increase was even greater.

“In light of our and other’s research, we theorize that factors including a high glycemic load may stimulate the body’s production of insulin,” Meyerhardt said. “That, in turn, may increase the proliferation of cells and prevent the natural cell-death process in cancer cells that have metastasized from their original site.”

Meyerhardt added that while the study doesn’t prove that diets high in glycemic load and carbohydrate intake cause recurrence of colon cancer, the results strongly suggest that such dietary factors play a role. “Our findings may offer useful guidance for patients and physicians in ways of improving patient survival after treatment.”


The senior author of the study is Charles Fuchs, MD, MPH, of Dana-Farber. Co-authors are Kaori Sato, MS, Robert Mayer, MD, and Devin Wigler, of Dana-Farber; Donna Niedzwiecki, PhD, and Cynthia Ye of Cancer and Leukemia Group B Statistical Center, Duke University Medical Center; Leonard Saltz, MD, of Memorial Sloan-Kettering Cancer Center; Rex Mowat, MD, of Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, MD, of Hopital du Sacre-Coeur de Montréal, Canada; Alexander Hantel, MD, of Loyola University Stritch School of Medicine, Maywood, IL; Al Benson, MD, of Northwestern University; and Alan Venook, MD, of the University of California at San Francisco.
The study was supported in part by grants from the National Cancer Institute (CA31946, CA33601, R01 CA118553, RO1 CA149222, and GI SPORE grant P50 CA127003), and Pfizer Oncology.
Dana-Farber Cancer Institute